Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50626 |
Name | gastrointestinal neuroendocrine tumor |
Definition | A gastrointestinal system cancer that has_material_basis_in neuroendocrine cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastrointestinal neuroendocrine tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
NCT02687958 | Phase II | Everolimus | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | Active, not recruiting | ITA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02955069 | Phase II | Spartalizumab | Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 1 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT03043664 | Phase Ib/II | Lanreotide acetate + Pembrolizumab | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) | Completed | USA | 0 |
NCT03049189 | Phase III | 177Lu-edotreotide Everolimus | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 4 |
NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
NCT03278379 | Phase II | Avelumab | Avelumab in G2-3 NET (NET-002) | Unknown status | CAN | 0 |
NCT03278405 | Phase Ib/II | Avelumab | Avelumab in G3 NEC (NET-001) | Completed | CAN | 0 |
NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |
NCT03420521 | Phase II | Ipilimumab + Nivolumab | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Terminated | USA | 0 |
NCT03670030 | Phase II | Nab-rapamycin | A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | Terminated | USA | 0 |
NCT03870399 | Phase II | Tamoxifen | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) | Active, not recruiting | USA | 1 |
NCT03879694 | Phase I | Octreotide + Sargramostim + SurVaxM | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT03891784 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
NCT03972488 | Phase III | Octreotide acetate lutetium Lu 177 dotatate + Octreotide acetate | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03980925 | Phase II | Carboplatin + Etoposide + Nivolumab | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | Active, not recruiting | ESP | 0 |
NCT04086485 | Phase Ib/II | lutetium Lu 177 dotatate + Olaparib | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | Recruiting | USA | 0 |
NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Active, not recruiting | ESP | 0 |
NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
NCT04525638 | Phase II | lutetium Lu 177 dotatate + Nivolumab | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | Recruiting | ESP | 0 |
NCT04609592 | Phase I | lutetium Lu 177 dotatate | Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Recruiting | USA | 0 |
NCT04893785 | Phase II | Cabozantinib + Temozolomide | A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) | Recruiting | ITA | 0 |
NCT04919226 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT05249114 | Phase I | Cabozantinib + lutetium Lu 177 dotatate | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT05262556 | Phase I | Ipilimumab + Nivolumab + Thymoquinone | TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas | Recruiting | USA | 0 |
NCT05364944 | Phase I | Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) | Active, not recruiting | ITA | GBR | FRA | ESP | DEU | 3 |
NCT05475210 | Phase I | 177Lu-DOTA-EB-TATE | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05477576 | Phase Ib/II | Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) | Recruiting | USA | NLD | FRA | ESP | CAN | BEL | 1 |
NCT05554003 | Phase II | Temozolomide | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) | Recruiting | ITA | 0 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ESP | AUS | 3 |
NCT05652686 | Phase I | PT217 | A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
NCT05701241 | FDA approved | Lanreotide acetate Octreotide acetate | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) | Recruiting | NLD | BEL | 0 |
NCT05746208 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05997056 | Phase II | Nab-rapamycin | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Recruiting | USA | 0 |
NCT06016855 | FDA approved | lutetium Lu 177 dotatate | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | Recruiting | USA | 0 |